Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC)
Anlotinib combined with TEC as neoadjuvant therapy demonstrated manageable toxicity and promising antitumor activity for locally advanced TNBC. Further investigation of this combination regimen is warranted.
Authors
- Kuojun Ren (ORCID: https://orcid.org/0000-0001-6435-6987)
- Tingbo Ye (ORCID: https://orcid.org/0009-0007-8459-9119)
- Shuhan Wang (ORCID: https://orcid.org/0000-0001-8677-7192)
- Shengying Wang
- Jianjun Liu (ORCID: https://orcid.org/0000-0002-3255-3019)
- Zhengzhi Zhu (ORCID: https://orcid.org/0009-0007-0175-3759)
- Shikai Hong
Institutions
- University of Science and Technology of China (CN)
- Anhui Provincial Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1186/s12885-024-12852-z
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China